SavedAdd your journal

Journals / Dicle Tıp Dergisi / 2019 / Cilt: 46 - Sayı: 2

Primary Plasma Cell Leukemia: Case Report

Primer Plazma Hücreli Lösemi: Olgu Sunumu

SİNAN DEMİRCİOĞLU
Ali DOĞAN
Murat ALTINBAŞAK
CENGİZ DEMİR
Pages
393–396
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Bortezomib based regimens and autologous stem cell transplantation are recommended for treatment.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Plasma cell leukemia (PHL) is a rare form of plasma cell dyscrasias.
📊
Key Findings & Data:There are two forms of primary and secondary PHL.
💡
Conclusion & Impact:Bortezomib based regimens and autologous stem cell transplantation are recommended for treatment.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Plasma cell leukemia (PHL) is a rare form of plasma cell dyscrasias. There are two forms of primary and secondary PHL. The prognosis is very poor. Since the morphology does not resemble mature plasma cells, there may be confusion in the diagnosis. Bortezomib based regimens and autologous stem cell transplantation are recommended for treatment.

Özet

Plazma hücreli lösemi (PHL), plazma hücreli diskrazilerin nadir görülen bir formudur. Primer ve sekonder PHL olmak üzere iki formu vardır. Prognozu oldukça kötüdür. Morfolojik olarak matür plazma hücrelerine benzememesi sebebiyle tanıda karışıklıklar olabilmektedir. Tedavide bortezomib bazlı rejimler ve otolog kök hücre nakli önerilmektedir.

🔖

Cite This Article

DEMİRCİOĞLU, S., DOĞAN, A., ALTINBAŞAK, M., DEMİR, C. (2019). Primary Plasma Cell Leukemia: Case Report. Dicle Tıp Dergisi, Cilt: 46 - Sayı: 2, 393–396. https://ajindex.com/articles/189659

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Sant M, Allemani C, Tereanu C, et all. Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project. Blood 2010; 116: 3724-34
  2. Noel P, Kyle RA. Plasma cell leukemia: an evaluation of response to therapy. The American journal of medicine 1987; 83: 1062-8
  3. Tiedemann RE, Gonzalez-Paz N, Kyle RA, et all. Genetic aberrations and survival in plasma cell leukemia. Leukemia 2008; 22: 1044-52
  4. Fernandez de Larrea C, Kyle RA, Durie BG, et all. Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group. Leukemia 2013; 27: 780-91
  5. Garcia-Sanz R, Orfao A, Gonzalez M, et all. Primary plasma cell leukemia: clinical, immunophenotypic, DNA ploidy, and cytogenetic characteristics. Blood 1999; 93: 1032-7
  6. Greipp PR, Raymond NM, Kyle RA, O'Fallon WM. Multiple myeloma: significance of plasmablastic subtype in morphological classification. Blood 1985; 65: 305-10
  7. Kyle RA, Gertz MA, Witzig TE, et all. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc 2003; 78: 21-33
  8. Blade J, Kyle RA. Multiple myeloma in young patients: clinical presentation and treatment approach. Leuk Lymphoma 1998; 30: 493-501
  9. Gonsalves WI, Rajkumar SV, Go RS, et all. Trends in survival of patients with primary plasma cell leukemia: a population-based analysis. Blood 2014; 124: 907-12
  10. Musto P. Progress in the Treatment of Primary Plasma Cell Leukemia. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 2016; 34: 2082-4
  11. Musto P, Simeon V, Martorelli MC, et all. Lenalidomide and low-dose dexamethasone for newly diagnosed primary plasma cell leukemia. Leukemia 2014; 28: 222-5
  12. Royer B, Minvielle S, Diouf M, et all. Bortezomib, Doxorubicin, Cyclophosphamide, Dexamethasone Induction Followed by Stem Cell Transplantation for Primary Plasma Cell Leukemia: A Prospective Phase II Study of the Intergroupe Francophone du Myelome. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 2016; 34: 2125- 32
  13. Jung SH, Lee JJ, Kim K, et all. The role of frontline autologous stem cell transplantation for primary plasma cell leukemia: a retrospective multicenter study (KMM160). Oncotarget 2017; 8: 79517-26
  14. Granell M, Calvo X, Garcia-Guinon A, et all. Prognostic impact of circulating plasma cells in patients with multiple myeloma: i